TABLE 18Definitions of molecular response in high-dose imatinib studies

StudyOutcome reportedDefinition
Breccia et al. (2010)9MMRBCR–ABL/ABL ratio < 0.1%
Complete molecular responseBCR–ABL/ABL ratio < 0.001
Kantarjian et al. (2007),6 (2009)7MMRBCR–ABL level ≤ 0.1 on the international scale based on standard methodology (references cited)
Koh et al. (2010)10Early molecular responseA molecular reduction > 50% within 6 months

From: 3, Clinical effectiveness

Cover of Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.23.
Loveman E, Cooper K, Bryant J, et al.
Southampton (UK): NIHR Journals Library; 2012 May.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.